The World Health Organization has granted prequalification approval to Artemether-lumefantrine, marking the first antimalarial formulation designed specifically for newborns and infants. This designation confirms that the medicine meets global standards for quality, safety, and effectiveness.

The World Health Organization announced on Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time. Artemether-lumefantrine is the first antimalarial formulation designed specifically for the youngest victims of the mosquito-borne disease. “The prequalification designation indicates that the medicine meets international standards of quality, safety and efficacy,” the WHO said in a statement. Up to now, infants have been treated with.....